The Institute for Molecular Medicine (IMM), a non-profit scientific research organization established in 1996 with the goal of understanding, preventing and curing chronic diseases, including neurodegenerative disorders, today announced the licensing of its universal vaccine platform technology, MultiTEP, to a new startup biotechnology company, Nuravax.
September 29, 2021
· 3 min read